Newport Research Announces Receiving Patent for Novel Cyclosporine Dry Eye Therapy

Plus, Company Receives Allowance for Second Patent for Innovative Cyclosporine Dry Eye Therapy

NEWPORT BEACH, Calif.–(BUSINESS WIRE)–Today, Newport Research, which develops formulations, products, processes, packages and technologies for the pharmaceutical industry, announces receiving a patent and having a second patent allowed for a novel cyclosporine dry eye therapy. The Company’s intellectual property portfolio, which includes additional pending patents, covers a broad formulation platform of a unique suspension comprising aqueous, amorphous nanodispersions of cyclosporine. This intellectual property and formulation platform will form the basis for an entry into the global over $1.5 billion dry eye prescription eye drops market.

The currently available branded and generic prescription cyclosporine products in the dry eye market are mostly emulsions. Emulsions have been shown to have low bioavailability in the eye and to produce poor patient outcomes. Notably, the Newport Research flexible formulation platform overcomes known deficiencies of current cyclosporine eye drops by being designed to have higher bioavailability for better efficacy and improved dry eye relief.

“We are excited to have been granted and allowed two patents for our novel cyclosporine dry eye therapy,” commented Harun Takruri, PhD, Inventor and CEO of Newport Research. “Our unrivaled suspension formulations can contain much higher concentrations of cyclosporine than formulations comprising emulsions or solutions. And our preliminary animal bioavailability data confirms higher ocular bioavailability when compared to the market leader.”

About Newport Research

Newport Research, Inc. develops formulations, products, processes, packages and technologies for the pharmaceutical industry. The Company, celebrating its 25-year anniversary, specializes in sterile and non-sterile liquid and semi-solid products. It delivers value for its customers in areas such as special-purpose formulations, project management, technology evaluations and clinical supply services.

Contacts

Orlando Rodrigues

COR Communications

760.212.5727

[email protected]